Compare Adaptive Biotechnologies Corp (ADPT) vs Public Storage (PSA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Public Storage — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Public Storage trades at $319.92 (market cap $57.71B). The key difference: Public Storage is far larger — about 17.3× Adaptive Biotechnologies Corp's market cap, and Public Storage pays a 3.65% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PSA | |
|---|---|---|
Market Cap | $3.33B | $57.71B |
Sector | Health | Real Estate |
52-Week High | $22.37 | $329.64 |
52-Week Low | $10.24 | $258.44 |
Enterprise Value | $3.19B | $71.96B |
Dividend Yield | — | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Public Storage (PSA) trades at $328.69, near analyst consensus targets, with a slight 0.29% dip. The stock shows strong technical momentum with bullish moving averages and support at $321. Fundamentally, PSA maintains robust profitability with a 39.16% net margin and consistent earnings beats, though valuation multiples like P/E of 33.47 appear elevated. Recent developments include a $1.2B Canadian acquisition and enhanced liquidity facilities, signaling growth initiatives.
Outlook remains positive driven by operational strength and strategic expansions, but risks include high valuation sensitivity and interest rate exposure. Analyst consensus leans Hold (62.86%), with a $330.38 price target suggesting limited near-term upside. Investors should weigh solid fundamentals against premium pricing in a normalized REIT environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
